PMC:7784786 / 15432-15747
Annnotations
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
543 | 208-216 | Species | denotes | patients | Tax:9606 |
544 | 306-314 | Species | denotes | patients | Tax:9606 |
545 | 0-10 | Chemical | denotes | Itolizumab | MESH:C000597346 |
546 | 232-242 | Chemical | denotes | itolizumab | MESH:C000597346 |
547 | 56-90 | Disease | denotes | opportunistic secondary infections | MESH:D060085 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T136 | 0-91 | Sentence | denotes | Itolizumab was very safe and did not seem to exacerbate opportunistic secondary infections. |
T137 | 92-217 | Sentence | denotes | Unfortunately, we did no measure neither the frequency nor the total amount of circulating T cells in these initial patients. |
T138 | 218-315 | Sentence | denotes | The impact of itolizumab on circulating T cells are being implementing in new recruited patients. |